

Special Issue

Development of Therapies for Shiga Toxin

Message from the Guest Editor

Gastrointestinal *E. coli*-derived Shiga toxin (verotoxin) remains the major cause of acute pediatric renal failure—the hemolytic uremic syndrome. Despite more than 30 years of research, there is no effective treatment to prevent the pathology of toxin-induced HUS. However, recent studies have expanded the scope and knowledge of Stx-induced pathology, and have sparked novel approaches to treatment/prevention which provide hope that effective therapy is on the horizon
Prof. Dr. Clifford A. Lingwood

Guest Editor

Prof. Dr. Clifford Lingwood

Molecular Medicine Peter Gilgan Centre for Research & Learning, The Hospital for Sick Children, 686 Bay Street, Toronto, ON M5G 0A4, Canada

Deadline for manuscript submissions

closed (31 August 2022)



Toxins

an Open Access Journal
by MDPI

Impact Factor 4.0
CiteScore 8.2
Indexed in PubMed



mdpi.com/si/106162

Toxins
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
toxins@mdpi.com

[mdpi.com/journal/
toxins](https://mdpi.com/journal/toxins)





Toxins

an Open Access Journal
by MDPI

Impact Factor 4.0
CiteScore 8.2
Indexed in PubMed



[mdpi.com/journal/
toxins](https://mdpi.com/journal/toxins)



About the Journal

Message from the Editor-in-Chief

Toxinology is an incredibly diverse area of study, ranging from field surveys of environmental toxins to the study of toxin action at the molecular level. The editorial board and staff of *Toxins* are dedicated to providing a timely, peer-reviewed outlet for exciting, innovative primary research articles and concise, informative reviews from investigators in the myriad of disciplines contributing to our knowledge on toxins. We are committed to meeting the needs of the toxin research community by offering useful and timely reviews of all manuscripts submitted. Please consider *Toxins* when submitting your work for publication.

Editor-in-Chief

Prof. Dr. Jay Fox

Department of Microbiology, University of Virginia, Charlottesville, VA,
USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, AGRIS, and other databases.

Journal Rank:

JCR - Q1 (Toxicology) / CiteScore - Q1 (Toxicology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 20.3 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the second half of 2024).